Exanthem subitum (human herpesvirus-6 reactivation) after autologous stem cell transplantation

2016 ◽  
Vol 18 (2) ◽  
pp. 255-256 ◽  
Author(s):  
S. Schlaweck ◽  
J. Brägelmann ◽  
P. Brossart ◽  
K. Mayer
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Human Herpesvirus ◽  
Human Herpesvirus 6 ◽  
Exanthem Subitum ◽  
Herpesvirus 6

scholarly journals New Rising Infection: Human Herpesvirus 6 Is Frequent in Myeloma Patients Undergoing Autologous Stem Cell Transplantation after Induction Therapy with Bortezomib

2012 ◽  
Vol 2012 ◽  
pp. 1-7 ◽  
Author(s):  
Netanel Horowitz ◽  
Ilana Oren ◽  
Noa Lavi ◽  
Tsila Zuckerman ◽  
Noam Benyamini ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Autologous Stem Cell Transplantation ◽  
Group Versus ◽  
Human Herpesvirus ◽  
Patient Characteristics ◽  
Unexplained Fever ◽  
Herpesvirus 6 ◽  
Viral Screening

Herpesvirus 6 (HHV-6) infection is a common complication during immunosuppression. Its significance for multiple myeloma (MM) patients undergoing autologous stem cell transplantation (ASCT) after treatment with novel agents affecting immune system remains undetermined. Data on 62 consecutive MM patients receiving bortezomib-dexamethasone (VD) (; 66%) or thalidomide-dexamethasone (TD) (, 34%) induction, together with melphalan 200 mg/m2 autograft between 01.2005 and 09.2010, were reviewed. HHV-6 reactivation was diagnosed in patients experiencing postengraftment unexplained fever (PEUF) in the presence of any level of HHHV-6 DNA in blood. There were no statistically significant differences in patient characteristics between the groups, excluding dexamethasone dosage, which was significantly higher in patients receiving TD. Eight patients in TD and 18 in VD cohorts underwent viral screening for PEUF. HHV-6 reactivation was diagnosed in 10 patients of the entire series (16%), accounting for 35% of those screened; its incidence was 19.5% () in the VD group versus 9.5% () in the TD group. All patients recovered without sequelae. In conclusion, HHV-6 reactivation is relatively common after ASCT, accounting for at least a third of PEUF episodes. Further studies are warranted to investigate whether bortezomib has an impact on HHV-6 reactivation development.

scholarly journals Transmission of Integrated Human Herpesvirus 6 through Stem Cell Transplantation: Implications for Laboratory Diagnosis

2006 ◽  
Vol 193 (7) ◽  
pp. 912-916 ◽  
Author(s):  
Duncan A. Clark ◽  
Elisabeth P. Nacheva ◽  
Hoe Nam Leong ◽  
Diana Brazma ◽  
Ying Ting Li ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Human Herpesvirus ◽  
Laboratory Diagnosis ◽  
Human Herpesvirus 6 ◽  
Herpesvirus 6
Sign in / Sign up

Export Citation Format

Share Document